Of note, mice treated with aldometanib did not exhibit changes of heart weight, or display changes in heart glycogen content (determined by PAS staining and biochemical assay) or morphological appearance (by H&E staining; Extended Data Fig. 10a–c), indicating that aldometanib does not cause cardiac hypertrophy as seen in mice treated with direct AMPK agonists37. The gene discussed is PRKAA2; the disease is cardiac hypertrophy.